Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
Pacific Biosciences of California Inc (NASDAQ: PACB) closed the day trading at $2.43 up 4.74% from the previous closing price of $2.32. In other words, the price has increased by $4.74 from its previous closing price. On the day, 8.68 million shares were traded. PACB stock price reached its highest trading level at $2.445 during the session, while it also had its lowest trading level at $2.315.
Ratios:
For a better understanding of PACB, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.40 and its Current Ratio is at 6.24. In the meantime, Its Debt-to-Equity ratio is 19.40 whereas as Long-Term Debt/Eq ratio is at 19.38.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 18 ’25 when Van Oene Mark sold 26,836 shares for $1.31 per share. The transaction valued at 35,182 led to the insider holds 1,920,035 shares of the business.
MARK VAN OENE bought 26,836 shares of PACB for $35,174 on Aug 18 ’25. On May 19 ’25, another insider, Farmer Michele, who serves as the insider of the company, sold 5,195 shares for $1.00 each. As a result, the insider received 5,200 and left with 269,259 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PACB now has a Market Capitalization of 733635072 and an Enterprise Value of 1138061056. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.75 while its Price-to-Book (P/B) ratio in mrq is 20.32. Its current Enterprise Value per Revenue stands at 7.362 whereas that against EBITDA is -5.909.
Stock Price History:
The Beta on a monthly basis for PACB is 2.18, which has changed by 0.17171717 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, PACB has reached a high of $2.72, while it has fallen to a 52-week low of $0.85. The 50-Day Moving Average of the stock is 34.29%, while the 200-Day Moving Average is calculated to be 72.35%.
Shares Statistics:
Over the past 3-months, PACB traded about 8.72M shares per day on average, while over the past 10 days, PACB traded about 10968260 shares per day. A total of 301.85M shares are outstanding, with a floating share count of 270.83M. Insiders hold about 10.29% of the company’s shares, while institutions hold 52.59% stake in the company. Shares short for PACB as of 1763078400 were 33569699 with a Short Ratio of 3.85, compared to 1760486400 on 34508178. Therefore, it implies a Short% of Shares Outstanding of 33569699 and a Short% of Float of 12.640001000000002.
Earnings Estimates
Currently, 8.0 analysts are dedicated to thoroughly evaluating and rating the performance of Pacific Biosciences of California Inc (PACB) in the stock market.The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.12 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.53 and -$0.56 for the fiscal current year, implying an average EPS of -$0.54. EPS for the following year is -$0.5, with 7.0 analysts recommending between -$0.42 and -$0.54.
Revenue Estimates
8 analysts predict $41.82M in revenue for. The current quarter. It ranges from a high estimate of $43M to a low estimate of $40.4M. As of. The current estimate, Pacific Biosciences of California Inc’s year-ago sales were $39.22MFor the next quarter, 8 analysts are estimating revenue of $41.31M. There is a high estimate of $44M for the next quarter, whereas the lowest estimate is $38.7M.
A total of 8 analysts have provided revenue estimates for PACB’s current fiscal year. The highest revenue estimate was $158.17M, while the lowest revenue estimate was $155.8M, resulting in an average revenue estimate of $157.22M. In the same quarter a year ago, actual revenue was $154.01MBased on 8 analysts’ estimates, the company’s revenue will be $177.14M in the next fiscal year. The high estimate is $184.6M and the low estimate is $165.2M.
